<DOC>
	<DOCNO>NCT00195806</DOCNO>
	<brief_summary>The purpose study determine long-term treatment , 1 year , Depakote ER safe reduction occurrence migraine headaches adolescent .</brief_summary>
	<brief_title>Study Designed Evaluate Safety Prophylactic Depakote ER Treatment Adolescents With Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Subject subject 's legal representative voluntarily sign date IRBapproved informed assent form IRBapproved inform consent form , respectively , studyspecific procedure test perform ; Subject male , nonpregnant , nonlactating female ; Subject 12 17 year age , inclusive , Screening Visit ; Subject weigh least 77 lb . ( i.e. , 35 kg ) ; Subject currently diagnosis migraine headache consistent International Headache Society ( IHS ) criterion ; Subject judge generally good health base result medical history , physical examination , 12lead electrocardiogram ( ECG ) , laboratory profile ; In investigator 's opinion , subject benefit Depakote ER migraine prophylaxis . History allergic reaction significant sensitivity valproate similar drug ; History noncompliance medication medical instruction ; Recent ( previous 6 month ) history drug and/or alcohol abuse positive urine drug screen , Screening Visit , drug abuse ( e.g. , amphetamine , barbiturate , benzodiazepine , cocaine , opiates , phencyclidine [ PCP ] ) ; Female , childbearing potential , use effective method birth control ( e.g. , total sexual abstinence contraceptive ) judge investigator . Use follow medication class specific drug list : antidepressant , antiepileptic drug ( AEDs ) aspirin and/or aspirincontaining product chronic use systemic corticosteroid , clonazepam , diazepam , erythromycin , ethosuximide , pemoline , phenobarbital , rifampin , tolbutamide , zidovudine anticoagulant drug therapy ; Any serious medical psychiatric disorder ( ) , include epilepsy obesity , may confound interpretation result study ; Central nervous system ( CNS ) neoplasm , CNS infection , demyelinate disease , degenerative neurological disease , progressive CNS disease ; History encephalopathy , hepatitis , pancreatitis , ureacycle disorder underlie condition/disease , might interfere study drug absorption completion study drug therapy evaluation throughout duration trial ; Screening laboratory result indicate presence Hepatitis B surface antigen ( HBsAg ) , Hepatitis C antibody known history positive test result HIV ; Screening laboratory result indicate : 1 . Platelet count =/ &lt; 100,000/uL 2 . ALT AST =/ &gt; 2 time Upper Limit Normal ( ULN ) ; Receipt investigational drug within 30 day prior study drug administration schedule receive investigational drug anytime study ; Participation prior Depakote ER migraine study ( M02488 M02554 ) ; reason , subject consider investigator unsuitable candidate receive Depakote participate study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Depakote ER</keyword>
	<keyword>Divalproex sodium</keyword>
</DOC>